-
Auditing and Monitoring
-
Compliance
-
COVID-19
- Articles
- CDC Updates from February 5, 2021 and Later
- CLIA (Clinical Laboratory Improvement Amendments)
- Employer's Guide to COVID-19 – HR Toolkit CGI Business Solutions
- FEMA
- Group Activities - COVID-19
- Infection Control
- PPE (Personal Protective Equipment)
- Quarantine and Isolation Guidelines COVID-19
- Reopening COVID-19
- Restrictions COVID-19
- Survey Resources COVID-19
- Testing COVID-19
- Treatment COVID-19
- Vaccinations COVID-19
- Visitation COVID-19
- Waivers COVID-19
- Immunizations COVID-19
-
Education
-
Efficiency
-
FAQ
-
Manual
-
MDS
-
Rehabilitation
-
Regulatory
-
Reimbursement
- Appeals and Denied Claims Management
- Bundled Payment
- Case Mix - CO, RUG-III 34 Grouper
- Case Mix CT- (Not Case Mix)
- Case Mix DC, RUG-IV 48 Grouper
- Case Mix GA, RUG-III 34 Grouper
- Case Mix HI, RUG-III 34 Grouper
- Case Mix ID, RUG-IV 48 Grouper
- Case Mix IL, RUG-IV 48 Grouper
- Case Mix IN, RUG-IV 48 Grouper
- Case Mix IA, RUG-III 34 Grouper
- Case Mix KS, RUG-III 34 Grouper
- Case Mix KY, RUG-III 34 Grouper
- Case Mix LA RUG-III 34 Grouper
- Case Mix ME, RUG III 44 Grouper
- Case Mix TX, RUG-III 34 Grouper
- Case Mix
- Consolidated Billing
- Home Care
- Medicaid
- Medicare Part B
- MMQ
- PDPM
- Proposed Rule
- RCS (Resident Classification System)
- RUGs
- Telehealth
- Value-Based Purchasing
- FAQ
-
Survey
-
Respiratory Therapy
How should the use of Compazine be coded on the MDS?
Compazine is a first generation antipsychotic medication, it is sometimes used for psychiatric indications, but it is most commonly used for nausea and vomiting. Based on MDS coding guidelines it should be coded not based on its intent or reason for use but based on its classification.
Regardless of the intent of the use the MDS coding should be based on the classification of the drug. The side effects listed for compazine include the same extrapyrmidal adverse effects as other antipsychotic medications and the facility is responsible for monitoring for these adverse effects